About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Neoantigen Cancer Vaccine Market Analysis, Size, Report to 2030
Neoantigen Cancer Vaccine Market

Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis Report By Product (Personalised neo-antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing), By Delivery Mechanism (Liposomes, Virosomes, Gene gun, Electroporation, Others), By Application (Lung, Melanoma, Gastrointestinal, Brain cancer, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI2008DR
Last Updated : May 09, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Neoantigen Cancer Vaccine Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Personalised neo-antigen vaccine
        1. By Value
      3. Off-the-shelf neoantigen vaccine
        1. By Value
    3. By Neoantigen Type
      1. Introduction
        1. Neoantigen Type By Value
      2. Synthetic Long Peptide
        1. By Value
      3. Nucleic acid
        1. By Value
      4. Dendritic cell
        1. By Value
      5. Tumour cell
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous
        1. By Value
      3. Intramuscular
        1. By Value
      4. Transdermal
        1. By Value
      5. Others
        1. By Value
    5. By Cell
      1. Introduction
        1. Cell By Value
      2. Autologous
        1. By Value
      3. Allogenic
        1. By Value
    6. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Sequencing
        1. By Value
      3. Whole Genome Sequencing
        1. By Value
      4. HLA Typing
        1. By Value
    7. By Delivery Mechanism
      1. Introduction
        1. Delivery Mechanism By Value
      2. Liposomes
        1. By Value
      3. Virosomes
        1. By Value
      4. Gene gun
        1. By Value
      5. Electroporation
        1. By Value
      6. Others
        1. By Value
    8. By Application
      1. Introduction
        1. Application By Value
      2. Lung
        1. By Value
      3. Melanoma
        1. By Value
      4. Gastrointestinal
        1. By Value
      5. Brain cancer
        1. By Value
      6. Others
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Personalised neo-antigen vaccine
        1. By Value
      3. Off-the-shelf neoantigen vaccine
        1. By Value
    3. By Neoantigen Type
      1. Introduction
        1. Neoantigen Type By Value
      2. Synthetic Long Peptide
        1. By Value
      3. Nucleic acid
        1. By Value
      4. Dendritic cell
        1. By Value
      5. Tumour cell
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous
        1. By Value
      3. Intramuscular
        1. By Value
      4. Transdermal
        1. By Value
      5. Others
        1. By Value
    5. By Cell
      1. Introduction
        1. Cell By Value
      2. Autologous
        1. By Value
      3. Allogenic
        1. By Value
    6. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Sequencing
        1. By Value
      3. Whole Genome Sequencing
        1. By Value
      4. HLA Typing
        1. By Value
    7. By Delivery Mechanism
      1. Introduction
        1. Delivery Mechanism By Value
      2. Liposomes
        1. By Value
      3. Virosomes
        1. By Value
      4. Gene gun
        1. By Value
      5. Electroporation
        1. By Value
      6. Others
        1. By Value
    8. By Application
      1. Introduction
        1. Application By Value
      2. Lung
        1. By Value
      3. Melanoma
        1. By Value
      4. Gastrointestinal
        1. By Value
      5. Brain cancer
        1. By Value
      6. Others
        1. By Value
    9. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Personalised neo-antigen vaccine
          1. By Value
        3. Off-the-shelf neoantigen vaccine
          1. By Value
      2. By Neoantigen Type
        1. Introduction
          1. Neoantigen Type By Value
        2. Synthetic Long Peptide
          1. By Value
        3. Nucleic acid
          1. By Value
        4. Dendritic cell
          1. By Value
        5. Tumour cell
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous
          1. By Value
        3. Intramuscular
          1. By Value
        4. Transdermal
          1. By Value
        5. Others
          1. By Value
      4. By Cell
        1. Introduction
          1. Cell By Value
        2. Autologous
          1. By Value
        3. Allogenic
          1. By Value
      5. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Sequencing
          1. By Value
        3. Whole Genome Sequencing
          1. By Value
        4. HLA Typing
          1. By Value
      6. By Delivery Mechanism
        1. Introduction
          1. Delivery Mechanism By Value
        2. Liposomes
          1. By Value
        3. Virosomes
          1. By Value
        4. Gene gun
          1. By Value
        5. Electroporation
          1. By Value
        6. Others
          1. By Value
      7. By Application
        1. Introduction
          1. Application By Value
        2. Lung
          1. By Value
        3. Melanoma
          1. By Value
        4. Gastrointestinal
          1. By Value
        5. Brain cancer
          1. By Value
        6. Others
          1. By Value
    10. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Personalised neo-antigen vaccine
        1. By Value
      3. Off-the-shelf neoantigen vaccine
        1. By Value
    3. By Neoantigen Type
      1. Introduction
        1. Neoantigen Type By Value
      2. Synthetic Long Peptide
        1. By Value
      3. Nucleic acid
        1. By Value
      4. Dendritic cell
        1. By Value
      5. Tumour cell
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous
        1. By Value
      3. Intramuscular
        1. By Value
      4. Transdermal
        1. By Value
      5. Others
        1. By Value
    5. By Cell
      1. Introduction
        1. Cell By Value
      2. Autologous
        1. By Value
      3. Allogenic
        1. By Value
    6. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Sequencing
        1. By Value
      3. Whole Genome Sequencing
        1. By Value
      4. HLA Typing
        1. By Value
    7. By Delivery Mechanism
      1. Introduction
        1. Delivery Mechanism By Value
      2. Liposomes
        1. By Value
      3. Virosomes
        1. By Value
      4. Gene gun
        1. By Value
      5. Electroporation
        1. By Value
      6. Others
        1. By Value
    8. By Application
      1. Introduction
        1. Application By Value
      2. Lung
        1. By Value
      3. Melanoma
        1. By Value
      4. Gastrointestinal
        1. By Value
      5. Brain cancer
        1. By Value
      6. Others
        1. By Value
    9. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Personalised neo-antigen vaccine
          1. By Value
        3. Off-the-shelf neoantigen vaccine
          1. By Value
      2. By Neoantigen Type
        1. Introduction
          1. Neoantigen Type By Value
        2. Synthetic Long Peptide
          1. By Value
        3. Nucleic acid
          1. By Value
        4. Dendritic cell
          1. By Value
        5. Tumour cell
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous
          1. By Value
        3. Intramuscular
          1. By Value
        4. Transdermal
          1. By Value
        5. Others
          1. By Value
      4. By Cell
        1. Introduction
          1. Cell By Value
        2. Autologous
          1. By Value
        3. Allogenic
          1. By Value
      5. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Sequencing
          1. By Value
        3. Whole Genome Sequencing
          1. By Value
        4. HLA Typing
          1. By Value
      6. By Delivery Mechanism
        1. Introduction
          1. Delivery Mechanism By Value
        2. Liposomes
          1. By Value
        3. Virosomes
          1. By Value
        4. Gene gun
          1. By Value
        5. Electroporation
          1. By Value
        6. Others
          1. By Value
      7. By Application
        1. Introduction
          1. Application By Value
        2. Lung
          1. By Value
        3. Melanoma
          1. By Value
        4. Gastrointestinal
          1. By Value
        5. Brain cancer
          1. By Value
        6. Others
          1. By Value
    10. Germany
    11. France
    12. Spain
    13. Italy
    14. Russia
    15. Nordic
    16. Benelux
    17. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Personalised neo-antigen vaccine
        1. By Value
      3. Off-the-shelf neoantigen vaccine
        1. By Value
    3. By Neoantigen Type
      1. Introduction
        1. Neoantigen Type By Value
      2. Synthetic Long Peptide
        1. By Value
      3. Nucleic acid
        1. By Value
      4. Dendritic cell
        1. By Value
      5. Tumour cell
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous
        1. By Value
      3. Intramuscular
        1. By Value
      4. Transdermal
        1. By Value
      5. Others
        1. By Value
    5. By Cell
      1. Introduction
        1. Cell By Value
      2. Autologous
        1. By Value
      3. Allogenic
        1. By Value
    6. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Sequencing
        1. By Value
      3. Whole Genome Sequencing
        1. By Value
      4. HLA Typing
        1. By Value
    7. By Delivery Mechanism
      1. Introduction
        1. Delivery Mechanism By Value
      2. Liposomes
        1. By Value
      3. Virosomes
        1. By Value
      4. Gene gun
        1. By Value
      5. Electroporation
        1. By Value
      6. Others
        1. By Value
    8. By Application
      1. Introduction
        1. Application By Value
      2. Lung
        1. By Value
      3. Melanoma
        1. By Value
      4. Gastrointestinal
        1. By Value
      5. Brain cancer
        1. By Value
      6. Others
        1. By Value
    9. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Personalised neo-antigen vaccine
          1. By Value
        3. Off-the-shelf neoantigen vaccine
          1. By Value
      2. By Neoantigen Type
        1. Introduction
          1. Neoantigen Type By Value
        2. Synthetic Long Peptide
          1. By Value
        3. Nucleic acid
          1. By Value
        4. Dendritic cell
          1. By Value
        5. Tumour cell
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous
          1. By Value
        3. Intramuscular
          1. By Value
        4. Transdermal
          1. By Value
        5. Others
          1. By Value
      4. By Cell
        1. Introduction
          1. Cell By Value
        2. Autologous
          1. By Value
        3. Allogenic
          1. By Value
      5. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Sequencing
          1. By Value
        3. Whole Genome Sequencing
          1. By Value
        4. HLA Typing
          1. By Value
      6. By Delivery Mechanism
        1. Introduction
          1. Delivery Mechanism By Value
        2. Liposomes
          1. By Value
        3. Virosomes
          1. By Value
        4. Gene gun
          1. By Value
        5. Electroporation
          1. By Value
        6. Others
          1. By Value
      7. By Application
        1. Introduction
          1. Application By Value
        2. Lung
          1. By Value
        3. Melanoma
          1. By Value
        4. Gastrointestinal
          1. By Value
        5. Brain cancer
          1. By Value
        6. Others
          1. By Value
    10. Korea
    11. Japan
    12. India
    13. Australia
    14. Taiwan
    15. South East Asia
    16. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Personalised neo-antigen vaccine
        1. By Value
      3. Off-the-shelf neoantigen vaccine
        1. By Value
    3. By Neoantigen Type
      1. Introduction
        1. Neoantigen Type By Value
      2. Synthetic Long Peptide
        1. By Value
      3. Nucleic acid
        1. By Value
      4. Dendritic cell
        1. By Value
      5. Tumour cell
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous
        1. By Value
      3. Intramuscular
        1. By Value
      4. Transdermal
        1. By Value
      5. Others
        1. By Value
    5. By Cell
      1. Introduction
        1. Cell By Value
      2. Autologous
        1. By Value
      3. Allogenic
        1. By Value
    6. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Sequencing
        1. By Value
      3. Whole Genome Sequencing
        1. By Value
      4. HLA Typing
        1. By Value
    7. By Delivery Mechanism
      1. Introduction
        1. Delivery Mechanism By Value
      2. Liposomes
        1. By Value
      3. Virosomes
        1. By Value
      4. Gene gun
        1. By Value
      5. Electroporation
        1. By Value
      6. Others
        1. By Value
    8. By Application
      1. Introduction
        1. Application By Value
      2. Lung
        1. By Value
      3. Melanoma
        1. By Value
      4. Gastrointestinal
        1. By Value
      5. Brain cancer
        1. By Value
      6. Others
        1. By Value
    9. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Personalised neo-antigen vaccine
          1. By Value
        3. Off-the-shelf neoantigen vaccine
          1. By Value
      2. By Neoantigen Type
        1. Introduction
          1. Neoantigen Type By Value
        2. Synthetic Long Peptide
          1. By Value
        3. Nucleic acid
          1. By Value
        4. Dendritic cell
          1. By Value
        5. Tumour cell
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous
          1. By Value
        3. Intramuscular
          1. By Value
        4. Transdermal
          1. By Value
        5. Others
          1. By Value
      4. By Cell
        1. Introduction
          1. Cell By Value
        2. Autologous
          1. By Value
        3. Allogenic
          1. By Value
      5. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Sequencing
          1. By Value
        3. Whole Genome Sequencing
          1. By Value
        4. HLA Typing
          1. By Value
      6. By Delivery Mechanism
        1. Introduction
          1. Delivery Mechanism By Value
        2. Liposomes
          1. By Value
        3. Virosomes
          1. By Value
        4. Gene gun
          1. By Value
        5. Electroporation
          1. By Value
        6. Others
          1. By Value
      7. By Application
        1. Introduction
          1. Application By Value
        2. Lung
          1. By Value
        3. Melanoma
          1. By Value
        4. Gastrointestinal
          1. By Value
        5. Brain cancer
          1. By Value
        6. Others
          1. By Value
    10. Turkey
    11. Saudi Arabia
    12. South Africa
    13. Egypt
    14. Nigeria
    15. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Personalised neo-antigen vaccine
        1. By Value
      3. Off-the-shelf neoantigen vaccine
        1. By Value
    3. By Neoantigen Type
      1. Introduction
        1. Neoantigen Type By Value
      2. Synthetic Long Peptide
        1. By Value
      3. Nucleic acid
        1. By Value
      4. Dendritic cell
        1. By Value
      5. Tumour cell
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Intravenous
        1. By Value
      3. Intramuscular
        1. By Value
      4. Transdermal
        1. By Value
      5. Others
        1. By Value
    5. By Cell
      1. Introduction
        1. Cell By Value
      2. Autologous
        1. By Value
      3. Allogenic
        1. By Value
    6. By Technology
      1. Introduction
        1. Technology By Value
      2. RNA Sequencing
        1. By Value
      3. Whole Genome Sequencing
        1. By Value
      4. HLA Typing
        1. By Value
    7. By Delivery Mechanism
      1. Introduction
        1. Delivery Mechanism By Value
      2. Liposomes
        1. By Value
      3. Virosomes
        1. By Value
      4. Gene gun
        1. By Value
      5. Electroporation
        1. By Value
      6. Others
        1. By Value
    8. By Application
      1. Introduction
        1. Application By Value
      2. Lung
        1. By Value
      3. Melanoma
        1. By Value
      4. Gastrointestinal
        1. By Value
      5. Brain cancer
        1. By Value
      6. Others
        1. By Value
    9. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Personalised neo-antigen vaccine
          1. By Value
        3. Off-the-shelf neoantigen vaccine
          1. By Value
      2. By Neoantigen Type
        1. Introduction
          1. Neoantigen Type By Value
        2. Synthetic Long Peptide
          1. By Value
        3. Nucleic acid
          1. By Value
        4. Dendritic cell
          1. By Value
        5. Tumour cell
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Intravenous
          1. By Value
        3. Intramuscular
          1. By Value
        4. Transdermal
          1. By Value
        5. Others
          1. By Value
      4. By Cell
        1. Introduction
          1. Cell By Value
        2. Autologous
          1. By Value
        3. Allogenic
          1. By Value
      5. By Technology
        1. Introduction
          1. Technology By Value
        2. RNA Sequencing
          1. By Value
        3. Whole Genome Sequencing
          1. By Value
        4. HLA Typing
          1. By Value
      6. By Delivery Mechanism
        1. Introduction
          1. Delivery Mechanism By Value
        2. Liposomes
          1. By Value
        3. Virosomes
          1. By Value
        4. Gene gun
          1. By Value
        5. Electroporation
          1. By Value
        6. Others
          1. By Value
      7. By Application
        1. Introduction
          1. Application By Value
        2. Lung
          1. By Value
        3. Melanoma
          1. By Value
        4. Gastrointestinal
          1. By Value
        5. Brain cancer
          1. By Value
        6. Others
          1. By Value
    10. Mexico
    11. Argentina
    12. Chile
    13. Colombia
    14. Rest of LATAM
    1. Neoantigen Cancer Vaccine Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. OSE Immunotherapeutics SA
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Gritstone bio Inc.
    3. BioNTech SE
    4. Hoffmann-La Roche Ltd.
    5. Pfizer Inc.
    6. Merck & Co. Inc.
    7. Moderna Inc.
    8. Avidea Technologies Inc.
    9. Eli Lilly and Company
    10. Vaccibody AS
    11. Agenus Inc.
    12. Novogene Co. Ltd.
    13. ZIOPHARM Oncology Inc.
    14. ISA Pharmaceuticals B.V.
    15. BrightPath Biotherapeutics Co. Ltd.
    16. Vaximm AG
    17. Medigene AG
    18. Genocea Biosciences Inc.
    19. Advaxis Inc.
    20. Nouscom AG
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Bispecific Antibodies Market Size The global bispecific antibodies market size was valued at USD 11.84 billion in 2024 and is expected to grow from USD 17.10 billion in 2025 to USD 323.21 billion by 2033, growing at a CAGR of 44.4% du
Buy Now
Global Report
The global X-Ray Inspection System Market size was valued at USD 734.5 Million in 2022 and is projected to reach USD 1231.3 Million by 2031, registering a CAGR of 6.6% during the forecast period (2023-2031). The rising awareness of the bene
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.